The Native Antigen Company (now part of LGC’s Clinical Diagnostics Division), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has introduced its custom contract service to rapidly develop antigen panels for influenza A and B viruses. This new service offers scientists access to high-quality proteins from emerging seasonal and pandemic influenza strains, to support ongoing research and development of diagnostics and vaccines.
The Native Antigen Company provides custom contract services to develop panels of the influenza antigens from a wide range of virus strains and subtypes using its proprietary HEK293 mammalian expression system (VirtuE), which is able to introduce proper protein folding and full glycosylation to closely mimic naturally occurring proteins.
The Company has already used this recombinant protein expression system to successfully develop a range of haemagglutinin and neuraminidase proteins for influenza A and B viruses, both of which spread routinely in humans and are responsible for seasonal flu epidemics each year. Its custom contract service could help researchers working with specific strains of influenza gain rapid access to highly purified proteins to conduct detailed assessments of immune responses with diagnostics, including vaccination responses to particular strains.
For more information, visit: thenativeantigencompany.com/influenza-services-landing-page
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/flu_virus__1_.jpg116211523wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00The Native Antigen Company introduces custom contract service for influenza researchers
Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development. They are now available to scientists and diagnostic developers worldwide via Absolute Antibody’s online catalogue.
The new antibodies were generated from the blood cells of an infected COVID-19 patient and have shown in a recent study to display neutralizing activity against SARS-CoV-2. Two antibody clones (CV1 and CV30) each bound the SARS-CoV-2 spike glycoprotein, with CV30 also shown to bind the receptor binding domain (RBD) and inhibit the interaction with the host cell receptor ACE2. Both antibodies are now available in a variety of species, isotypes and subtypes designed to extend their usefulness in COVID-19 applications.
Absolute Antibody offers the SARS-CoV-2 antibodies in human formats such as IgG1, IgG3, IgM and IgA, for use in neutralization assays and as serological controls in COVID-19 diagnostic tests. In addition, the antibodies are available in species such as mouse and rabbit for detection applications and co-labelling studies; fragment formats for better tissue penetration and in vivo imaging; and with engineered Fc Silent domains to facilitate research into antibody-dependent enhancement. All antibodies are recombinantly produced for ensured batch-to-batch reproducibility, high purity and low endotoxin levels.
The new neutralizing antibodies join Absolute Antibody’s full collection of engineered coronavirus reagents, including the spike glycoprotein antibody clone CR3022, nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in diagnostic tests.
Absolute Antibody is also supporting coronavirus research by providing antibody engineering and manufacturing services, including the production of gram quantities of human antibodies sequenced from recovering COVID-19 patients.
For more information, visit: https://absoluteantibody.com/general/sars-cov-2-neutralizing-antibodies
Thermo Fisher Scientific has launched the Thermo Scientific Smart-Vue Pro, a next-generation remote monitoring solution for biotechnology, pharmaceutical, clinical and academic laboratories. The device is designed to enable superior levels of sample protection, workflow efficiencies, asset/cost optimization and regulatory compliance.
With the option for an on-premise or cloud setup, the Thermo Scientific Smart-Vue Pro Remote Monitoring Solution provides real-time, continuous monitoring of critical laboratory equipment parameters and immediately notifies users about off-limit measurements that, if left unattended, could compromise sample safety and integrity. Notifications are delivered by email, text message or phone call, through a secure network, prompting corrective action.
Importantly, the Smart-Vue Pro solution delivers fully traceable data logging and secure user-level access to the complete system functionality at anytime from anywhere with Internet access, facilitating compliance with a wide range of regulatory standards, including 21CFR Part 11 and cGxP.
Operating on the LoRaWAN (Long-Range Wide Area Network) technology, the Smart-Vue Pro solution can simultaneously monitor conditions across several laboratories located on different floors or buildings. The LoRaWAN technology ensures a single receiver can cover up to 2km line of sight in urban areas, eliminating the need to invest in multiple monitoring systems. Scalability is further enhanced through the advanced modular, customizable architecture of the Smart-Vue Pro solution that supports up to four pre-calibrated Smart Digital Sensors. As a result, the system can monitor many pieces of equipment or multiple parameters within one piece of equipment at the same time. Finally, the Smart-Vue Pro solution allows for easy expansion to accommodate additional pieces of equipment without the need for costly upgrades. Overall, this improved scalability results in considerable installation, hardware and maintenance cost savings.
The Smart-Vue Pro solution features an interactive, colour touchscreen that displays data along with visual and audio alarms for at-a-glance monitoring, while enabling simplified and customizable views for an enhanced user experience.
Thermo Fisher Scientific supports the Smart-Vue Pro solution with end-to-end service and support packages to guide users through installation, validation, implementation and maintenance.
The Smart-Vue Pro solution is capable of monitoring temperatures ranging from −200°C to +150°C, relative humidity and dry contact state, with CO2 concentration and differential pressure set to be added to the system’s measurement capabilities in the near future.
For more information, visit: www.thermofisher.com/smartvuepro
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/Thermo_Scientific_Smart-Vue__1_-scaled.jpg256014623wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Thermo Fisher launches Smart-Vue Pro to ensure sample protection with remote monitoring
Abingdon Health has received the CE mark for its COVID-19 antibody test, called AbC-19TM Rapid Test. The test is now approved for professional use in the UK and EU.
The test uses a small drop of blood from a finger-prick and shows results in 20 minutes, without the need to send a sample to a lab.
The test will now be mass produced with roll out expected from the end of August. The company says it will produce 500,000 COVID-19 antibody tests a month from October and one million a month from January 2021.
AbC-19 Rapid Test detects IgG antibodies to the SARS-CoV-2 virus with 99.4% accuracy according to the company. Testing was performed at the Ulster University and at the laboratories of Abingdon Health.
Chris Yates, Abingdon Health CEO, said: “This UK designed, developed and manufactured high-quality rapid diagnostic test is a breakthrough for UK life sciences and a triumph of British business.
“It has been a company-wide effort at Abingdon Health to achieve this milestone in such a short space of time. Our research and development teams have been working two shifts a day, seven days a week, to develop the test. We have deployed nearly fifteen times the number of people that would be on a typical project to deliver this test as quickly as possible.”
Abingdon Health is a UK-based medical device manufacturer. To develop and mass produce the volumes needed for the UK population, Abingdon Health set up and led the UK-Rapid Test Consortium (UK-RTC) in April this year. The consortium brings together the UK’s largest rapid test medical manufacturers, working together to provide capacity for delivery of more than a million tests per month.
The tests will also undergo ease of use trials with the general public to allow the Medical and Healthcare products Regulatory Agency to provide the necessary approvals for it to be used by the public as a home test which is expected in the coming months. These trials will be performed in conjunction with the Ulster University, using around 2000 volunteers.
For more information, visit: www.abingdonhealth.com
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/abingdon_health.jpg91012863wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Abingdon Health receives CE mark for COVID-19 antibody rapid test
AMS Biotechnology offers a comprehensive range of end-to-end services for exosome purification, characterization, and engineering.
Exosomes are small endosome-derived lipid nanoparticles, actively secreted by exocytosis in most living cells. Acting on tissues in both the local environment and further afield, they function as important signal carriers through their transport of RNA, proteins, lipids and DNA. Exosomes are involved in a wide range of normal and pathogenic processes, making exosome research crucial in multiple areas. Exosomes are a type of extracellular vesicle (EV) that show promise for use as unique drug carriers to deliver protease inhibitors to treat COVID-19.
In this application, EVs may provide targeted delivery of protease inhibitors, with fewer systemic side effects. More importantly, EVs are highly suitable for major aseptic processing and can be upscaled for mass production.
The Exosome Isolation & Quantification Service from AMSBIO provides reliable and reproducible isolation of exosomes from almost any biofluid ranging from plasma and tissue culture media to cerebrospinal fluid. Using this service, exosomes are isolated by ultracentrifugation and quality assessed using a NanoDrop spectrophotometer. Options are also available to isolate by differential/gradient ultracentrifugation, immunoaffinity, size exclusion chromatography, precipitation/low speed centrifugation.
For scientists interested in exosome miRNA isolation and sequencing, AMSBIO offer a service to extract RNA from exosomes, and subject it to the Small RNA-Sequencing. In addition, basic analysis will be performed on the raw data, and screening for specific miRNA can also be performed.
AMSBIO also offers analysis of exosome surface proteins using MACSPlex kit. For proteomics analysis, samples will be analysed by LC/Q-TOF mass spectrometry to characterize the peptides formed. The analysed samples are also differentially analysed using molecular features finder and mass profiler to determine changes in the peptide profile. The resultant MS/MS data from the selected peptides will be imported into Spectrum Mill proteomic server software to identify the protein that is consistent with the imported peptide sequence. Both NCBInr and Swiss-Prot databases are available to search for users of this service.
In addition, AMSBIO can undertake a wide range of exosome functional assays including exosome-induced cell proliferation, exosome induced collagen production, Exosome-induced inhibition of inflammatory cytokines and In vitro wound healing (scratch assay).
For further information, visit: www.amsbio.com/exosome-research-services
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/amsbiopr272b.jpg2873593wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00AMSBIO offers customised solutions for exosome-related research
BioChromato, a respected Japanese manufacturer of high-quality products for chemical laboratories, reports that it has installed more than 1200 units of its Smart Evaporator C1 – a compact system that delivers rapid concentration or complete drying of samples in even high boiling solvents such as DMSO, DMF or water.
Designed to be easy to use, the Smart Evaporator C1 is an affordably priced system optimised to concentrate or dry single samples directly from any tube or vial (up to 32 mm neck diameter).
Drawing upon BioChromato’s patented spiral plug evaporation technology, the compact, benchtop Smart Evaporator C1 offers fast and effective evaporation in tubes or vials without solvent bumping thereby eliminating risk of sample loss, cross contamination and saving researchers time.
Proven to be the ideal lab tool for simple removal of high boiling point solvents, the C1 also excels at safe drying temperature sensitive compounds and efficient evaporation of small volume samples.
The Smart Evaporator C1 is optimised to handle solvent volumes up to 40 mL which can be extremely useful for concentrating compounds after organic synthesis or drying analytical samples at relatively high speeds. The versatile C1 can also take small tubes and vials (e.g. 1.5mL) where solvent volumes can be as little as 0.1ml (or less).
For more information, visit: https://biochromato.com/smart-evaporator/
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/biochromato_C1_Smart_Evaporator.jpg140014003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00BioChromato’s compact benchtop evaporator for DMSO & DMF samples proves popular with labs
BioChromato has introduced a gamma sterilized version of its popular RAPID Slit Seal for scientists looking to eliminate solvent evaporation from samples when culturing cells in 96-well microplates.
The RAPID Slit Seal is a proprietary self-closing microplate seal that returns to its original state even when punched with an HPLC or LC/MS autosampler. As a result, loss of volatile solvents from samples is eliminated.
In addition, with RAPID Slit Seal, insertion of pipette tips and sampling needles is easier and can be achieved without dragging.
In addition, with RAPID Slit Seal, insertion of pipette tips and sampling needles is easier and can be achieved without dragging.
For further information, visit: www.bicr.biz/product/consumables/rapid-slit-seal
CytoSMART Technologies has launched an automated organoid counter. The software application detects organoids using bright-field image analysis and runs on the Corning Cell Counter, a CytoSMART product.
Manually counting organoids is a routine part of laboratory operations, but is time consuming and user dependent. To overcome these issues CytoSMART has introduced this organoid counting application.
Joffry Maltha, CEO at CytoSMART Technologies, explained: “The 3D cellular structures that are formed in organoids have great potential in drug discovery and developmental biology. This has fuelled the ever-growing interest in culturing new sub-types of organoids and optimization of current protocols. Growing organoids does however take a substantial amount of time and skill. We believe that implementation of an automated solution for organoid counting can really speed up day-to-day work in the lab and is a logical step towards further implementation of organoids in cell culture-based research.”
The main features of the CytoSMART Organoid Counter are:
The main features of the CytoSMART Organoid Counter are:
Low-cost – works with a common reusable glass hemocytometer. No consumables required.
Precise – software allows for data gating and image selection for statistical analysis.
For more information, visit: https://cytosmart.com/products/organoid-counting
Fujirebio Europe has received CE marking for their Lumipulse G SARS-CoV-2 Ag, a high-sensitivity antigen test for the fully automated CLEIA (chemiluminescent enzyme immunoassay) Lumipulse G system, and of the ESPLINE SARS-CoV-2 rapid antigen test. Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD) testing.
The Lumipulse G series are robust, fully automated CLEIA immunoassay instruments. The Lumipulse G1200 and G600II have a throughput of respectively 120 and 60 tests per hour and allow laboratory personnel to randomly load samples as needed. CLEIA technology and automated testing provides increased sensitivity, reproducibility and throughput.
The ESPLINE SARS-CoV-2 is an immunochromatographic rapid antigen test, and unlike other nucleic acid-based tests on the IVD market that also detect the SARS-CoV-2 gene with high sensitivity, the ESPLINE test does not require any special equipment. It is a cassette-style assay using a simple procedure, and it has a short reaction time of 30 min.
Both assays received Japanese regulatory approval in May and June 2020 for use with nasopharyngeal and saliva samples (Lumipulse only) as an aid in the diagnosis of SARS-CoV-2 infection.
“We are the first company to develop and provide a fully automated SARS-CoV-2 antigen testing solution, to be used on our Lumipulse G series, together with a rapid test device on the ESPLINE platform, and expect these innovations will have a positive impact on result turnaround times and laboratory throughput of COVID-19 testing,” said Christiaan De Wilde, CEO at Fujirebio Europe.
For more information, visit: www.fujirebio.com/en/products-solutions/lumipulser-g-sarscov2-ag
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/fujirebio_Lumipulse.jpg135018263wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Fujirebio Europe receives CE mark for automated Lumipulse G SARS-CoV-2 antigen assay and ESPLINE SARS-CoV-2 rapid antigen device
Horizon Discovery Group, a leader in the application of gene editing and gene modulation for cell line engineering, has added single cell RNAseq-linked pooled CRISPR screening to its CRISPR screening services portfolio. The platform offers high-quality screening data and biological insight to address critical gaps in target identification and validation.
This launch is the result of a collaboration, announced in 2018, to develop and apply this novel research tool to discover new biology essential for the development of future therapeutics. The biological insight gained from Horizon’s single cell RNAseq-linked CRISPR screening platform could help researchers gain further understanding into complex biological models and speed up the time from discovery to validation by integrating the effect of gene editing with complex gene expression mapping.
Horizon’s pooled format screens offer researchers access to highly robust whole-genome level analyses that yield quality data outputs. Currently, it can be challenging to adequately multiplex the data from these screens to evaluate complex biological phenomena occurring in a subset of edited cells. Coupling pooled CRISPR screening to single cell RNAseq allows the impact of CRISPR-based gene modification to be examined on a global transcriptomic scale at single cell resolution. This could enable scientists to address critical gaps in target identification and validation as they work to develop new and more effective therapeutics.
Terry Pizzie, Chief Executive Officer, Horizon Discovery, explained: “Pooled CRISPR-Cas9 knockout screens have become a linchpin in drug target identification and validation. The development of our single cell RNAseq-linked pooled CRISPR screening service provides a substantial advance to Horizon’s screening capabilities. Our continuing development of cutting-edge services, including CRISPR screens in primary human immune cells, means we can offer our customers unparalleled insights into the biology that will help to underpin future drug and cell-based therapeutics.”
For more information, visit: https://horizondiscovery.com/en/navigation/screening/functional-genomic-screening
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
The Native Antigen Company introduces custom contract service for influenza researchers
, /in Product News /by 3wmediaThe Native Antigen Company (now part of LGC’s Clinical Diagnostics Division), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has introduced its custom contract service to rapidly develop antigen panels for influenza A and B viruses. This new service offers scientists access to high-quality proteins from emerging seasonal and pandemic influenza strains, to support ongoing research and development of diagnostics and vaccines.
The Native Antigen Company provides custom contract services to develop panels of the influenza antigens from a wide range of virus strains and subtypes using its proprietary HEK293 mammalian expression system (VirtuE), which is able to introduce proper protein folding and full glycosylation to closely mimic naturally occurring proteins.
The Company has already used this recombinant protein expression system to successfully develop a range of haemagglutinin and neuraminidase proteins for influenza A and B viruses, both of which spread routinely in humans and are responsible for seasonal flu epidemics each year. Its custom contract service could help researchers working with specific strains of influenza gain rapid access to highly purified proteins to conduct detailed assessments of immune responses with diagnostics, including vaccination responses to particular strains.
Read more
Absolute Antibody offers researchers SARS-CoV-2 neutralizing antibodies derived from COVID-19 patients
, /in Product News /by 3wmediaAbsolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development. They are now available to scientists and diagnostic developers worldwide via Absolute Antibody’s online catalogue.
The new antibodies were generated from the blood cells of an infected COVID-19 patient and have shown in a recent study to display neutralizing activity against SARS-CoV-2. Two antibody clones (CV1 and CV30) each bound the SARS-CoV-2 spike glycoprotein, with CV30 also shown to bind the receptor binding domain (RBD) and inhibit the interaction with the host cell receptor ACE2. Both antibodies are now available in a variety of species, isotypes and subtypes designed to extend their usefulness in COVID-19 applications.
Absolute Antibody offers the SARS-CoV-2 antibodies in human formats such as IgG1, IgG3, IgM and IgA, for use in neutralization assays and as serological controls in COVID-19 diagnostic tests. In addition, the antibodies are available in species such as mouse and rabbit for detection applications and co-labelling studies; fragment formats for better tissue penetration and in vivo imaging; and with engineered Fc Silent domains to facilitate research into antibody-dependent enhancement. All antibodies are recombinantly produced for ensured batch-to-batch reproducibility, high purity and low endotoxin levels.
The new neutralizing antibodies join Absolute Antibody’s full collection of engineered coronavirus reagents, including the spike glycoprotein antibody clone CR3022, nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in diagnostic tests.
Absolute Antibody is also supporting coronavirus research by providing antibody engineering and manufacturing services, including the production of gram quantities of human antibodies sequenced from recovering COVID-19 patients.
Read more
Thermo Fisher launches Smart-Vue Pro to ensure sample protection with remote monitoring
, /in Product News /by 3wmediaThermo Fisher Scientific has launched the Thermo Scientific Smart-Vue Pro, a next-generation remote monitoring solution for biotechnology, pharmaceutical, clinical and academic laboratories. The device is designed to enable superior levels of sample protection, workflow efficiencies, asset/cost optimization and regulatory compliance.
With the option for an on-premise or cloud setup, the Thermo Scientific Smart-Vue Pro Remote Monitoring Solution provides real-time, continuous monitoring of critical laboratory equipment parameters and immediately notifies users about off-limit measurements that, if left unattended, could compromise sample safety and integrity. Notifications are delivered by email, text message or phone call, through a secure network, prompting corrective action.
Importantly, the Smart-Vue Pro solution delivers fully traceable data logging and secure user-level access to the complete system functionality at anytime from anywhere with Internet access, facilitating compliance with a wide range of regulatory standards, including 21CFR Part 11 and cGxP.
Operating on the LoRaWAN (Long-Range Wide Area Network) technology, the Smart-Vue Pro solution can simultaneously monitor conditions across several laboratories located on different floors or buildings. The LoRaWAN technology ensures a single receiver can cover up to 2km line of sight in urban areas, eliminating the need to invest in multiple monitoring systems. Scalability is further enhanced through the advanced modular, customizable architecture of the Smart-Vue Pro solution that supports up to four pre-calibrated Smart Digital Sensors. As a result, the system can monitor many pieces of equipment or multiple parameters within one piece of equipment at the same time. Finally, the Smart-Vue Pro solution allows for easy expansion to accommodate additional pieces of equipment without the need for costly upgrades. Overall, this improved scalability results in considerable installation, hardware and maintenance cost savings.
The Smart-Vue Pro solution features an interactive, colour touchscreen that displays data along with visual and audio alarms for at-a-glance monitoring, while enabling simplified and customizable views for an enhanced user experience.
Thermo Fisher Scientific supports the Smart-Vue Pro solution with end-to-end service and support packages to guide users through installation, validation, implementation and maintenance.
The Smart-Vue Pro solution is capable of monitoring temperatures ranging from −200°C to +150°C, relative humidity and dry contact state, with CO2 concentration and differential pressure set to be added to the system’s measurement capabilities in the near future.
Read more
Abingdon Health receives CE mark for COVID-19 antibody rapid test
, /in Product News /by 3wmediaAbingdon Health has received the CE mark for its COVID-19 antibody test, called AbC-19TM Rapid Test. The test is now approved for professional use in the UK and EU.
The test uses a small drop of blood from a finger-prick and shows results in 20 minutes, without the need to send a sample to a lab.
The test will now be mass produced with roll out expected from the end of August. The company says it will produce 500,000 COVID-19 antibody tests a month from October and one million a month from January 2021.
AbC-19 Rapid Test detects IgG antibodies to the SARS-CoV-2 virus with 99.4% accuracy according to the company. Testing was performed at the Ulster University and at the laboratories of Abingdon Health.
Chris Yates, Abingdon Health CEO, said: “This UK designed, developed and manufactured high-quality rapid diagnostic test is a breakthrough for UK life sciences and a triumph of British business.
“It has been a company-wide effort at Abingdon Health to achieve this milestone in such a short space of time. Our research and development teams have been working two shifts a day, seven days a week, to develop the test. We have deployed nearly fifteen times the number of people that would be on a typical project to deliver this test as quickly as possible.”
Abingdon Health is a UK-based medical device manufacturer. To develop and mass produce the volumes needed for the UK population, Abingdon Health set up and led the UK-Rapid Test Consortium (UK-RTC) in April this year. The consortium brings together the UK’s largest rapid test medical manufacturers, working together to provide capacity for delivery of more than a million tests per month.
The tests will also undergo ease of use trials with the general public to allow the Medical and Healthcare products Regulatory Agency to provide the necessary approvals for it to be used by the public as a home test which is expected in the coming months. These trials will be performed in conjunction with the Ulster University, using around 2000 volunteers.
Read more
AMSBIO offers customised solutions for exosome-related research
, /in Product News /by 3wmediaAMS Biotechnology offers a comprehensive range of end-to-end services for exosome purification, characterization, and engineering.
Exosomes are small endosome-derived lipid nanoparticles, actively secreted by exocytosis in most living cells. Acting on tissues in both the local environment and further afield, they function as important signal carriers through their transport of RNA, proteins, lipids and DNA. Exosomes are involved in a wide range of normal and pathogenic processes, making exosome research crucial in multiple areas. Exosomes are a type of extracellular vesicle (EV) that show promise for use as unique drug carriers to deliver protease inhibitors to treat COVID-19.
In this application, EVs may provide targeted delivery of protease inhibitors, with fewer systemic side effects. More importantly, EVs are highly suitable for major aseptic processing and can be upscaled for mass production.
The Exosome Isolation & Quantification Service from AMSBIO provides reliable and reproducible isolation of exosomes from almost any biofluid ranging from plasma and tissue culture media to cerebrospinal fluid. Using this service, exosomes are isolated by ultracentrifugation and quality assessed using a NanoDrop spectrophotometer. Options are also available to isolate by differential/gradient ultracentrifugation, immunoaffinity, size exclusion chromatography, precipitation/low speed centrifugation.
For scientists interested in exosome miRNA isolation and sequencing, AMSBIO offer a service to extract RNA from exosomes, and subject it to the Small RNA-Sequencing. In addition, basic analysis will be performed on the raw data, and screening for specific miRNA can also be performed.
AMSBIO also offers analysis of exosome surface proteins using MACSPlex kit. For proteomics analysis, samples will be analysed by LC/Q-TOF mass spectrometry to characterize the peptides formed. The analysed samples are also differentially analysed using molecular features finder and mass profiler to determine changes in the peptide profile. The resultant MS/MS data from the selected peptides will be imported into Spectrum Mill proteomic server software to identify the protein that is consistent with the imported peptide sequence. Both NCBInr and Swiss-Prot databases are available to search for users of this service.
In addition, AMSBIO can undertake a wide range of exosome functional assays including exosome-induced cell proliferation, exosome induced collagen production, Exosome-induced inhibition of inflammatory cytokines and In vitro wound healing (scratch assay).
Read more
BioChromato’s compact benchtop evaporator for DMSO & DMF samples proves popular with labs
, /in Product News /by 3wmediaBioChromato, a respected Japanese manufacturer of high-quality products for chemical laboratories, reports that it has installed more than 1200 units of its Smart Evaporator C1 – a compact system that delivers rapid concentration or complete drying of samples in even high boiling solvents such as DMSO, DMF or water.
Designed to be easy to use, the Smart Evaporator C1 is an affordably priced system optimised to concentrate or dry single samples directly from any tube or vial (up to 32 mm neck diameter).
Drawing upon BioChromato’s patented spiral plug evaporation technology, the compact, benchtop Smart Evaporator C1 offers fast and effective evaporation in tubes or vials without solvent bumping thereby eliminating risk of sample loss, cross contamination and saving researchers time.
Proven to be the ideal lab tool for simple removal of high boiling point solvents, the C1 also excels at safe drying temperature sensitive compounds and efficient evaporation of small volume samples.
The Smart Evaporator C1 is optimised to handle solvent volumes up to 40 mL which can be extremely useful for concentrating compounds after organic synthesis or drying analytical samples at relatively high speeds. The versatile C1 can also take small tubes and vials (e.g. 1.5mL) where solvent volumes can be as little as 0.1ml (or less).
Read more
BioChromato introduces sterile 96-well plate seal for cell culturing
, /in Product News /by 3wmediaBioChromato has introduced a gamma sterilized version of its popular RAPID Slit Seal for scientists looking to eliminate solvent evaporation from samples when culturing cells in 96-well microplates.
The RAPID Slit Seal is a proprietary self-closing microplate seal that returns to its original state even when punched with an HPLC or LC/MS autosampler. As a result, loss of volatile solvents from samples is eliminated.
In addition, with RAPID Slit Seal, insertion of pipette tips and sampling needles is easier and can be achieved without dragging.
In addition, with RAPID Slit Seal, insertion of pipette tips and sampling needles is easier and can be achieved without dragging.
Read more
CytoSMART Technologies introduces automated organoid counter
, /in Product News /by 3wmediaCytoSMART Technologies has launched an automated organoid counter. The software application detects organoids using bright-field image analysis and runs on the Corning Cell Counter, a CytoSMART product.
Manually counting organoids is a routine part of laboratory operations, but is time consuming and user dependent. To overcome these issues CytoSMART has introduced this organoid counting application.
Joffry Maltha, CEO at CytoSMART Technologies, explained: “The 3D cellular structures that are formed in organoids have great potential in drug discovery and developmental biology. This has fuelled the ever-growing interest in culturing new sub-types of organoids and optimization of current protocols. Growing organoids does however take a substantial amount of time and skill. We believe that implementation of an automated solution for organoid counting can really speed up day-to-day work in the lab and is a logical step towards further implementation of organoids in cell culture-based research.”
The main features of the CytoSMART Organoid Counter are:
Read more
Fujirebio Europe receives CE mark for automated Lumipulse G SARS-CoV-2 antigen assay and ESPLINE SARS-CoV-2 rapid antigen device
, /in Product News /by 3wmediaFujirebio Europe has received CE marking for their Lumipulse G SARS-CoV-2 Ag, a high-sensitivity antigen test for the fully automated CLEIA (chemiluminescent enzyme immunoassay) Lumipulse G system, and of the ESPLINE SARS-CoV-2 rapid antigen test. Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD) testing.
The Lumipulse G series are robust, fully automated CLEIA immunoassay instruments. The Lumipulse G1200 and G600II have a throughput of respectively 120 and 60 tests per hour and allow laboratory personnel to randomly load samples as needed. CLEIA technology and automated testing provides increased sensitivity, reproducibility and throughput.
The ESPLINE SARS-CoV-2 is an immunochromatographic rapid antigen test, and unlike other nucleic acid-based tests on the IVD market that also detect the SARS-CoV-2 gene with high sensitivity, the ESPLINE test does not require any special equipment. It is a cassette-style assay using a simple procedure, and it has a short reaction time of 30 min.
Both assays received Japanese regulatory approval in May and June 2020 for use with nasopharyngeal and saliva samples (Lumipulse only) as an aid in the diagnosis of SARS-CoV-2 infection.
“We are the first company to develop and provide a fully automated SARS-CoV-2 antigen testing solution, to be used on our Lumipulse G series, together with a rapid test device on the ESPLINE platform, and expect these innovations will have a positive impact on result turnaround times and laboratory throughput of COVID-19 testing,” said Christiaan De Wilde, CEO at Fujirebio Europe.
Read more
Horizon Discovery introduces single cell RNAseq-linked CRISPR screening service
, /in Product News /by 3wmediaHorizon Discovery Group, a leader in the application of gene editing and gene modulation for cell line engineering, has added single cell RNAseq-linked pooled CRISPR screening to its CRISPR screening services portfolio. The platform offers high-quality screening data and biological insight to address critical gaps in target identification and validation.
This launch is the result of a collaboration, announced in 2018, to develop and apply this novel research tool to discover new biology essential for the development of future therapeutics. The biological insight gained from Horizon’s single cell RNAseq-linked CRISPR screening platform could help researchers gain further understanding into complex biological models and speed up the time from discovery to validation by integrating the effect of gene editing with complex gene expression mapping.
Horizon’s pooled format screens offer researchers access to highly robust whole-genome level analyses that yield quality data outputs. Currently, it can be challenging to adequately multiplex the data from these screens to evaluate complex biological phenomena occurring in a subset of edited cells. Coupling pooled CRISPR screening to single cell RNAseq allows the impact of CRISPR-based gene modification to be examined on a global transcriptomic scale at single cell resolution. This could enable scientists to address critical gaps in target identification and validation as they work to develop new and more effective therapeutics.
Terry Pizzie, Chief Executive Officer, Horizon Discovery, explained: “Pooled CRISPR-Cas9 knockout screens have become a linchpin in drug target identification and validation. The development of our single cell RNAseq-linked pooled CRISPR screening service provides a substantial advance to Horizon’s screening capabilities. Our continuing development of cutting-edge services, including CRISPR screens in primary human immune cells, means we can offer our customers unparalleled insights into the biology that will help to underpin future drug and cell-based therapeutics.”
For more information, visit: https://horizondiscovery.com/en/navigation/screening/functional-genomic-screening
Read more